Teva Pharmaceutical Industries (TEVA) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $0.86
- Estimate
- $0.72
- Surprise
- +19.3%
- Revenue (period 2026-09-30)
- $4.39B
- Score at report (before → after)
- 4.9 → 4.9/10
Revenue source: xbrl.
How the report landed
Teva Pharmaceutical Industries (TEVA) beat the $0.72 estimate with adjusted EPS of $0.86 — a large 19.3% upside surprise. TrendMatrix's engine moved from Data Issue (4.9/10) to Hold at 4.9/10 after the report.
Coverage in the report window
- Teva Pharmaceutical Industries CEO Says Just-Launched Schizophrenia Drug Weltruza Won't See Significant Revenue Until Se — benzinga, 2026-11-03
Where TrendMatrix's rating stands now
TrendMatrix currently rates TEVA Hold at 4.9/10.
3 of the last 4 quarters beat the estimate; this quarter's +19.3% surprise compares with a +1.1% four-quarter average.
What supports the rating
- Sector modifier (Healthcare): +0.5
- Strong earnings beat streak (3/4)
What argues against it
- Concentration risk — Product: generic medicines (55.0%)
- Analyst target reached - limited upside remaining
- Near 52-week high (3.3% away)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $41.91
- Stop
- $39.43
The stock trades at 67.6× trailing but 13.5× forward earnings — consensus estimates already build in a substantial earnings recovery.
Risk check: trading volume is running 1.7× its average — elevated turnover around the report window.
Model outputs from TrendMatrix’s engine as of 2026-11-04 — shown for context, not personalized investment advice.
TEVA at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Drug Manufacturers - Specialty & Generic
- Market cap
- $48.88B
- P/E (fwd)
- 13.5
- P/E (ttm)
- 67.6
- 52-week range
- $20.11–$43.34
- Off 52-week high
- 3.3%
- RSI (14)
- 57
- Volume vs avg
- 1.69×
- Score today
- 4.9/10